Last reviewed · How we verify
Open-label CBP-307 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Open-label CBP-307 (Open-label CBP-307) — Connect Biopharm LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Open-label CBP-307 TARGET | Open-label CBP-307 | Connect Biopharm LLC | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Open-label CBP-307 CI watch — RSS
- Open-label CBP-307 CI watch — Atom
- Open-label CBP-307 CI watch — JSON
- Open-label CBP-307 alone — RSS
Cite this brief
Drug Landscape (2026). Open-label CBP-307 — Competitive Intelligence Brief. https://druglandscape.com/ci/open-label-cbp-307. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing